“…Torregrosa et al. 29 demonstrated that FOLFIRI-bevacizumab combination was associated with better survival after failure of first line FOLFOX-bevacizumab for mCRC. In short, standard chemotherapy in CRC plays the pivotal role despite the availability of different targeted approaches or immunotherapy.…”